Monkeypox - Informed Choice Washington

FACTS ABOUT MONKEYPOX

This page will be updated as the situation evolves and information is revealed.

Highlights:

Public fear or concern of monkeypox, a minor and self-resolving illness, is not scientifically warranted
Non-vaccine/drug prevention and treatment options exist for those at high-risk
Naturally acquired immunity is generally superior, broader, and more durable than vaccination
The Jynneos vaccine does not prevent infection, transmission, or symptoms per animal studies. There are no human effectiveness studies available (CDC did a study in Africa but did not disclose results–more data on this to come)
The Jynneos vaccine (licensed for both smallpox and monkeypox) maker is permanently shielded from liability under the Countermeasures Injury Compensation Program. This shield was broadened further by the recent EUA granted by the FDA and the NIH calling an unwarranted state of emergency.
1.3 – 2.1 % of subjects in small safety trials of Jynneos experienced Cardiac Adverse Events of Special Interest
Jynneos is a live attenuated vaccine which are usually contraindicated for those with HIV. In clinical safety trials (not effectiveness), 8% of HIV positive subjects had severe reactions and were unable to get 2nd dose, and 7% had worsening HIV symptoms
TPOXX is the antiviral smallpox drug being pushed by the CDC. It is experimental and all who agree to use it must sign a 5 page Informed Consent Letter that informs them they or their insurance company are responsible for any medical bills arising from harm from the product. It is covered under the Countermeasures Injury Compensation Program, which means the drug maker can’t be sued. Although use requires entering a clinical trial, CDC claims “its use does not constitute research involving human subjects as defined by 45 CFR 46.102.”

There is concern, based on studies of how COVID-19 shots impact the immune system, that individuals who receive one or more COVID shots are at increased risk of infections, including monkeypox and other viruses.

Amanda is right, taking it every 6 mo increases viral susceptibility, but also weakens the immune system and may explain outbreaks: adenovirus-41, MPX human to human transmission, and disabling EBV, VZV reactivation syndromes such as lymphomatous reaction, Ramsay-Hunt, shingles pic.twitter.com/IxygfDPAFQ

— Peter McCullough, MD MPH (@P_McCulloughMD) August 28, 2022

The Virus & Disease it Causes

Per the CDC: https://www.cdc.gov/poxvirus/monkeypox/index.html
Per Truth for Health Foundation: https://www.truthforhealth.org/2022/07/monkeypox-virus-facts-vs-fear/
The PCR test https://www.labcorp.com/infectious-disease/monkeypox

The Jynneos Vaccine

FDA Jynneos Page https://www.fda.gov/vaccines-blood-biologics/jynneos
FDA Emergency Use Authorization Fact Sheet (omits risk of cardiac adverse events; falsely states it is used to “prevent monkeypox disease” – animal studies show it does not prevent infection, transmission, or disease symptoms) https://www.fda.gov/media/160773/download
CDC Jynneos Vaccine Information Statement (VIS) https://www.cdc.gov/vaccines/hcp/vis/vis-statements/smallpox-monkeypox.pdf The VIS states, in bold, without a shred of safety or effectiveness science: “If you have been recommended to receive JYNNEOS (TM) due to an exposure to monkeypox virus, you should be vaccinated regardless of concurrent illnesses, pregnancy, breastfeeding, or weakened immune system.”

The VIS omits the Cardiac Adverse Events that occurred in 1.3 – 2.1% of recipients; they omit the high rate of adverse events and worsening of HIV issues in those with HIV.